Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | NQO1 | P15559 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25253884 | 0.89 | AR (0.48) | MAOBARESR1HSD17B3NQO1 | |
| SCHEMBL12155344 | 0.78 | NQO1 (0.61) | MAOBARESR1HSD17B3NQO1 | |
| SCHEMBL12155359 | 0.76 | VKORC1 (0.67) | MAOBARESR1HSD17B3NQO1 | |
| SCHEMBL28776464 | 0.75 | MAOB (0.67) | MAOBARESR1HSD17B3ACHE | |
| SCHEMBL31457913 | 0.74 | KDM4E (0.48) | ARESR1HSD17B3NQO1ELANE | |
| SCHEMBL15842508 | 0.74 | KDM4E (0.48) | ARESR1HSD17B3NQO1ELANE | |
| SCHEMBL29080531 | 0.74 | ABCG2 (0.56) | CYP2C9L3MBTL1 | |
| SCHEMBL30558208 | 0.74 | ABCG2 (0.56) | CYP2C9L3MBTL1 | |
| SCHEMBL12155348 | 0.73 | MAOB (0.53) | MAOBARESR1HSD17B3NQO1 | |
| SCHEMBL18702818 | 0.71 | NPC1 (0.44) | MAOBNQO1ELANEACHETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN (BE) | 2012-04-12 | — | — | US | disclosed |
| US-8097611-B2 | Sulfonyl-derivatives as novel or histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-20100240639-A1 | Sulfonyl-Derivatives as Novel or Histone Deacetylase | VAN EMELEN KRISTOF | 2010-09-23 | — | — | US | disclosed |
| US-7709487-B2 | anticancer agents; can be combined with other HDAC inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-04 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1485365-B1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-14 | — | — | EP | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | disclosed |
| EP-1485365-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076422-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| US-6420131-B1 | MONITORING PREFRENTIAL ENZYMATIC ACTIVITY; OBTAIN SAMPLE OF ENZYMATIC POLYPEPTIDE, INCUBATE WITH MODULATOR, EVALUATE THE MODULATOR ABILITY TO INHIBIT ENZYMATIC POLYPEPTIDE | GENTEST CORPORATION | 2002-07-16 | — | — | US | disclosed |
| EP-1210342-A1 | THE USE OF FLUORESCEIN ARYL ETHERS IN HIGH THROUGHPUT CYTOCHROME P450 INHIBITION ASSAYS | GENTEST CORPORATION (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001014361-A1 | THE USE OF FLUORESCEIN ARYL ETHERS IN HIGH THROUGHPUT CYTOCHROME P450 INHIBITION ASSAYS | GENTEST CORPORATION (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | MAOB 1492/4885AR 1487/4885ESR1 2621/4885 |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | HDAC1, HDAC11, HDAC4 | MAOB 454/4885AR 588/4885ESR1 2111/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | MAOB 1492/4885AR 1487/4885ESR1 2621/4885 |
| US-20100240639-A1 | Sulfonyl-Derivatives as Novel or Histone Deacetylase | HDAC3, HDAC1, HDAC11 | MAOB 1690/4885AR 1027/4885ESR1 2055/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | MAOB 1492/4885AR 1487/4885ESR1 2621/4885 |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | HDAC1, HDAC11, HDAC3 | MAOB 1215/4885AR 1015/4885ESR1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.